CASE STUDY PRA Cool Under Deadline Pressure Quick Regulatory Approvals and First Patient In Impress New ClientPRA Cool Under Deadline Pressure Quick Regulatory Approvals and First Patient In Impress New Client Primary Endpoint Response & overall survival PRA Services Clinical Operations Project Management Medical Monitoring Indication Colorectal Cancer Drug Class Antibody Study Phase II Business Segment Product Registration Regions Western Europe Asia Pacific STUDY DESCRIPTION A Phase II, open-label study to assess the efficacy and safety of Study Drug in combination with Cetuximab in pretreated subjects with KRAS mutant metastatic colorectal cancer PRA was selected to perform a Phase II colorectal cancer trial due to our knowledge from previous colorectal studies as

Join for free to read